ASCO Highlights

The ADJUBIL trial reveals that dual immune checkpoint blockade with durvalumab and tremelimumab without capecitabine offers a promising adjuvant therapy option with minimal toxicity for resectable biliary tract cancer.

Patients with TP53-mutated biliary tract cancer may have poorer prognoses but show enhanced responsiveness to immune checkpoint inhibitors, offering hope for tailored therapeutic strategies.

A novel triplet immunotherapy combining durvalumab, bevacizumab, and tremelimumab shows potential for improving survival in advanced hepatocellular and biliary tract cancers.

A novel bispecific antibody, rilvegostomig, combined with chemotherapy shows promising efficacy and safety in improving outcomes for patients with advanced biliary tract cancer.

Zanidatamab-hrii significantly improves survival in HER2-positive biliary tract cancer, offering new hope for patients with limited second-line treatment options.

Real-world data from US veterans confirm the safety and efficacy of ivosidenib in treating IDH1-mutated cholangiocarcinoma, offering hope for improved outcomes in this challenging cancer.

The TRITICC trial highlights a promising second-line therapy with trifluridine, tipiracil, and irinotecan for advanced cholangiocarcinoma, offering hope after failure of first-line treatment.

A cutting-edge circulating cell-free DNA fragmentomics approach combined with machine learning offers a noninvasive method for early detection of biliary tract cancer.

Efficacy and safety results from the randomized phase 2 ABC-07 trial was presented comparing the addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in patients with locally advanced cholangiocarcinoma (CCA).

The phase 2 BOLD-100-001 study evaluated the safety and efficacy of the novel BOLD-100 anticancer drug plus FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer (BTC).